XTL Biopharma (XTLB) Posts Breakeven Q4 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/28/2026

1. ORCL
2. AVGO
3. BA
4. CDNS
5. ANT
6. SPY
7. META
8. HOOD
9. STX
10. INTC

Go back to XTL Biopharma (XTLB) Posts Breakeven Q4 Loss

XTL Biopharmaceuticals Provides Financial and Operational Update For the Full Year Ended December 31, 2014

April 28, 2015 7:45 AM EDT

HERZLIYA, Israel, April 28, 2015 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"), a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of unmet clinical needs, today announced its financial and operational results for the full year ended December 31, 2014.  

Josh Levine, Chief Executive Officer of XTL, commented, "With the recent closing of a $4 million registered direct offering from a US based healthcare-dedicated investor... More